QURE has lost nearly half its value in five trading days, a collapse that sets up one of biotech's sharper contrasts right now: shorts sitting at 15% of the float are not pressing harder, yet the stock just handed them a 46% gain they never needed to chase.
The core tension is regulatory. The bull case rested on a relatively clean path to a BLA filing for AMT-130 in Huntington's disease, with the FDA's June Type B meeting having appeared to accept the 3-year Phase I/II dataset as the primary submission basis for accelerated approval. The bear case argued that path was always fragile, dependent on the FDA not reverting to its preference for a prospective, randomized, sham-surgery-controlled trial. This week's move suggests the market is repricing the probability that the easier route is less certain than it looked in June. Goldman Sachs' Salveen Richter, filing a note on the same day as the crash, cut her price target from $46 to $31 while keeping a Neutral rating, a rare moment where the most cautious voice on the Street still implies more than 25% upside from the closing price of $24.51.
The lending market tells a story that cuts against the idea of a coordinated short attack. Borrow availability is extraordinarily loose, with roughly 1,570% availability, meaning there are about 16 shares available to borrow for every one already borrowed. That is well above the 52-week tightest reading of 384%. Cost to borrow has barely moved, running at 0.40%, down 20% over the past month and carrying no sign of stress. Short interest itself edged slightly lower on the week, falling less than 1% to 15.1% of the free float. That is a meaningful absolute level, but the direction is not escalating. Options positioning adds a nuance: the put/call ratio of 0.29 is running more than two standard deviations above its 20-day average of 0.27, a mild elevation rather than an outright panic hedge, and the absolute level remains call-heavy by any standard. The 52-week high on PCR was above 1.0, so today's reading of 0.29 reflects a market still tilted toward calls even after the crash.
The Street was broadly bullish heading into this week's dislocation and largely remains so, though targets are now well above where the stock trades. Wells Fargo, Wolfe Research, Barclays, Mizuho, and HC Wainwright all raised or initiated positive ratings in July and late June, with targets ranging from $60 to $80. The consensus mean target now stands at roughly $59, implying more than 140% upside from current levels, a gap that either reflects conviction the selloff is overdone or targets that have not yet been revised down in bulk. Goldman's cut to $31 is the only fresh downward revision on the tape. Forward EPS momentum scores rank in the 20th percentile over 30 days, reflecting deteriorating near-term earnings expectations, though the 12-month forward EPS year-on-year improvement factor ranks in the 91st percentile, consistent with a company whose losses are expected to narrow materially as pipeline catalysts approach. EV/EBITDA and P/E multiples are negative given the pre-revenue stage, making valuation a function of probability-weighted pipeline outcomes rather than traditional screens.
Institutional positioning adds context on who is absorbing or sitting with the pain. Avoro Capital remains the largest holder at roughly 9.7% of shares, having added 768,000 shares in the most recently reported quarter. JP Morgan Asset Management, which crossed the 5% threshold in a July 13-G filing, added nearly two million shares in the period ending September 1. RTW Investments added 1.4 million shares to hold 5.7%. These are not positions that were recently taken at depressed prices, and the degree to which they add, hold, or reduce after this week's move will be among the more significant signals to track. On the insider side, all recent trades from the CEO and directors in late June and early July were pre-arranged under 10b5-1 plans, option exercises paired with sales, and carried low significance scores. There is no discretionary insider buying on the record to frame as a floor signal. Wikipedia page views for QURE registered a z-score of 4.5 on retail attention as of September 23, the highest available reading, a sign that retail engagement spiked sharply ahead of or alongside the selloff.
The next earnings event is scheduled for November 9, with 40 days to go. The two prior events on record both produced positive reactions, a 15% single-day gain in late July and a 4% gain in another period, though those prints landed in a very different tape. With a BLA filing for AMT-130 still targeted for the third quarter of 2026 now effectively past, confirmation of whether and when that filing was made or delayed is the single most important data point between now and November. The short score dropped to 55.8 on September 29 from 58.5 the prior session, its largest one-day fall in the visible history, worth watching to see whether that easing extends or reverses as the dust settles.
See the live data behind this article on ORTEX.
Open QURE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
